ABUS
Arbutus Biopharma Corporation
NASDAQ · Healthcare · Biotechnology · US
$5.15
+0.59%Margins
Gross margin
100.0%
EBITDA margin
84.3%
EBIT margin
81.0%
Net margin
84.2%
FCF margin
-13.6%
59.2%
Return on equity
55.9%
Return on assets
56.1%
Return on invested capital
0.66x
Asset turnover
-$24.6M
Cash from operations
$0.47
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026